NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. is a private biotech company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to form a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine. To date, NGM Bio has generated a pipeline of six drug candidates in various stages of development, including NGM282 that recently demonstrated proof-of-concept in a Phase 2 study in non-alcoholic steatohepatitis (NASH). We have many more in preclinical development. In 2015, we entered into a broad, strategic collaboration with Merck that will provide us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.
30 articles with NGM Biopharmaceuticals, Inc.
NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer
Dr. Lieu brings expansive clinical development expertise as NGM continues to advance its broad, diverse clinical portfolio
Collaboration will Continue to Focus on Discovery and Development of Novel Biologic Therapeutics Across a Range of Therapeutic Areas
Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Merck and NGM Biopharmaceuticals, Inc. today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
MK-3655 is a monoclonal antibody agonist of the b-Klotho/FGFR1c receptor complex. The drug is being studied to treat nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)
Single dose of NGM313 resulted in statistically significant reductions in liver fat content and multiple metabolic parameters of NASH and Type 2 diabetes
NGM Biopharmaceuticals, Inc., a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced preliminary histology data from open-label, single-blind, dose-finding expansion cohorts of its Phase 2 study evaluating its lead product candidate, NGM282, in patients with nonalcoholic steatohepatitis (NASH).
NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313
NGM Biopharmaceuticals, Inc. today announced multiple presentations at AASLD's The Liver Meeting® 2018, which will take place in San Francisco from November 9-13, 2018.
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer
Suzanne Sawochka Hooper Joins NGM's Board of Directors
NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Statistically significant and clinically meaningful improvements observed in MRI measures of liver fat and serum biomarkers of liver function, lipid metabolism and fibrosis
The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.
NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.
NGM Release: Study Published In Nature Reveals Molecular Pathway Of Weight-Controlling Hormone, Enabling The Discovery Of Multiple Drug Candidates For Obesity And Cachexia
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial
NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH
NGM To Present New Data On NGM282 At The European Association For The Study Of The Liver International Liver Congress 2015
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine